9PL Stock Chart & Stats
€0.01
>-€0.01(-9.09%)
At close: 4:00 PM EDT
€0.01
>-€0.01(-9.09%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.46M
Enterprise Value€6.14
Total Cash (Recent Filing)€895.00K
Total Debt (Recent Filing)€146.00K
Price to Earnings (P/E)―
Beta12.88
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€54.96K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthAccelerating revenue growth indicates improving commercial traction and a broader opportunity to scale the business. If sustained, stronger top-line expansion can help absorb fixed costs, support investment in diagnostics capabilities, and improve operating leverage over the next several quarters.
Gross Margin ImprovementThe higher gross margin suggests the company is retaining more value from each unit of revenue than it did previously. Maintaining this improvement would provide a stronger foundation for covering operating expenses and could support eventual profitability as revenue expands.
Modest Absolute DebtAlthough equity has weakened, the relatively small absolute debt burden limits the immediate fixed financing pressure on the business. This leaves more scope than a heavily indebted balance sheet would provide to direct future resources toward operations and commercial growth.
Bears Say
Deep And Persistent LossesSevere losses show that current revenue is not yet sufficient to support the company’s cost base, despite improved growth and gross margin. Continued negative EBIT and EBITDA reduce internal funding capacity and make a durable path to profitability dependent on substantial operating improvement.
Ongoing Cash BurnRecurring negative operating and free cash flow means the business has not demonstrated self-sustaining cash generation. Persistent burn can constrain investment, increase reliance on external funding, and leave less flexibility to withstand execution challenges while the company scales.
Equity ErosionThe sharp reduction in equity materially weakens the balance sheet and reduces the cushion available to absorb further losses. Even with small total debt, continued deterioration could restrict financial flexibility and increase the importance of achieving cash and earnings improvement.
GENinCode UK Ltd. News
9PL FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest stock price was <€0.01 and its highest was €0.08 in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is €7.46M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 11 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -€0.012 earnings per share for the quarter.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -€0.012 in its last earnings report. Following the earnings report the stock price went down -22.857%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in DE:9PL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.